Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Pozycja w akcjach #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Cena akcji
$19.30
Ostatnia synchronizacja: 2023-12-26
Kapitalizacja rynkowa
$72.77M
Zmiana (1 dzień)
6.22%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Aeglea BioTherapeutics, Inc. (AGLE)

Kategoria

Historia stopy dywidendy dla Aeglea BioTherapeutics, Inc. (AGLE)
Stopa dywidendy (TTM) dla Aeglea BioTherapeutics, Inc. (symbol akcji: AGLE) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Aeglea BioTherapeutics, Inc. (AGLE) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji